Carbon nanotubes as vaccine scaffolds

Advanced Drug Delivery Reviews

Volumn 65, Issue 15, 2013, Pages 2016-2022

  Scheinberg, David A ^a   McDevitt, Michael R ^a   Dao, Tao ^a   Mulvey, J Justin ^a   Feinberg, Evan ^a   Alidori, Simone ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Adjuvants; Antigen presenting cells; Carbon nanotubes; Vaccines

Indexed keywords

ADJUVANTS; ANTIGEN PRESENTING CELLS; CARBON NANOTUBES DISPLAYS; DENDRITIC CELLS; IMMUNOGENICITY; IN-VIVO; INFECTIOUS DISEASE; LOW TOXICITY;

ANTIGENS; VACCINES;

CARBON NANOTUBES;

ADJUVANT; ALPHA INTERFERON; ALUMINUM SALT; ANTIGEN; BETA INTERFERON; CARBON NANOTUBE; CYTOKINE; DRUG CARRIER; GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 12; INTERLEUKIN 2; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; MOLECULAR SCAFFOLD; NUCLEOTIDE BINDING OLIGOMERIZATION DOMAIN LIKE RECEPTOR; PATTERN RECOGNITION RECEPTOR; SAPONIN DERIVATIVE; TOLL LIKE RECEPTOR AGONIST; VACCINE;

ANTIGEN PRESENTING CELL; CELL ACTIVATION; CELL DIFFERENTIATION; CHEMICAL COMPOSITION; CHIRALITY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DENDRITIC CELL; DRUG DELIVERY SYSTEM; DRUG DEVELOPMENT; DRUG EFFICACY; DRUG STABILITY; DRUG STRUCTURE; IMMUNOGENICITY; IMMUNOSTIMULATION; MOLECULAR RECOGNITION; NATURAL KILLER CELL; PRIORITY JOURNAL; PURIFICATION; REVIEW; TH1 CELL; TOXICITY; VACCINATION;

ADJUVANTS; ANTIGEN PRESENTING CELLS; CARBON NANOTUBES; VACCINES;

ANIMALS; ANTIGEN-PRESENTING CELLS; ANTIGENS; COMMUNICABLE DISEASES; DENDRITIC CELLS; HUMANS; NANOTUBES, CARBON; NEOPLASMS; VACCINES;

EID: 84888868158     PISSN: 0169409X     EISSN: 18728294     Source Type: Journal    
DOI: 10.1016/j.addr.2013.07.013     Document Type: Review

References (105)

1. Mackall C.L. Spreading the wealth: antigen discovery in adult tumors can help hone the search for pediatric tumor antigens. J. Immunother. 2001, 24:281.
2. Farkas A.M., Finn O.J. Vaccines based on abnormal self-antigens as tumor-associated antigens: immune regulation. Semin. Immunol. 2010, 22:125.
3. Steinman R.M., Banchereau J. Taking dendritic cells into medicine. Nature 2007, 449:419.
4. Melief C.J.M. Cancer immunotherapy by dendritic cells. Immunity 2008, 29:372.
5. Dyall R., Bowne W.B., Weber L.W., LeMaoult J., Szabo P., Moroi Y., Piskun G., Lewis J.J., Houghton A.N., Nikolic-Zugic J. Heteroclitic immunization induces tumor immunity. J. Exp. Med. 1998, 188:155.
6. Houghton A.N., Guevara-Patino J.A. Immune recognition of self in immunity against cancer. J. Clin. Invest. 2004, 114:468.
7. Heath A.W., Playfair J.H.L. Cytokines as immunological adjuvants. Vaccine 1992, 10:427.
8. O'Hagan D.T., MacKichan M.L., Singh M. Recent developments in adjuvants for vaccines against infectious diseases. Biomol. Eng. 2001, 18:69.
9. Srivastava P.K., Menoret A., Basu S., Binder R.J., McQuade K.L. Heat shock proteins come of age: primitive functions acquire new roles in an adaptive world. Immunity 1998, 8:657.
10. Kojima C. Design of stimuli-responsive dendrimers. Expert Opin. Drug Deliv. 2010, 7:307.
11. Livingston P.O., Ragupathi G. Cancer vaccines targeting carbohydrate antigens. Hum. Vaccin. 2006, 2:137.
12. Xiang S.D., Scalzo-Inguanti K., Minigo G., Park A., Hardy C.L., Plebanski M. Promising particle-based vaccines in cancer therapy. Expert Rev. Vaccines 2008, 7:1103.
13. Fifis T., Gamvrellis A., Crimeen-Irwin B., Pietersz G.A., Li J., Mottram P.L., McKenzie I.F.C., Plebanski M. Size-dependent immunogenicity: therapeutic and protective properties of nano-vaccines against tumors. J. Immunol. 2004, 173:3148.
14. Mottram P.L., Leong D., Crimeen-Irwin B., Gloster S., Xiang S.D., Meanger J., Ghildyal R., Vardaxis N., Plebanski M. Type 1 and 2 immunity following vaccination is influenced by nanoparticle size: formulation of a model vaccine for respiratory syncytial virus. Mol. Pharm. 2007, 4:73.
15. Kostarelos K., Bianco A., Prato M. Promises, facts and challenges for carbon nanotubes in imaging and therapeutics. Nat. Nanotechnol. 2009, 4:627.
16. Dumortier H., Lacotte S., Pastorin G., Marega R., Wu W., Bonifazi D., Briand J.P., Prato M., Muller S., Bianco A. Functionalized carbon nanotubes are non-cytotoxic and preserve the functionality of primary immune cells. Nano Lett. 2006, 6:3003.
17. Mutlu G.M., Budinger G.R.S., Green A.A., Urich D., Soberanes S., Chiarella S.E., Alheid G.F., McCrimmon D.R., Szleifer I., Hersam M.C. Biocompatible nanoscale dispersion of single-walled carbon nanotubes minimizes in vivo pulmonary toxicity. Nano Lett. 2010, 10:1664.
18. Scheinberg D.A., Villa C.H., Escorcia F.E., McDevitt M.R. Conscripts of the infinite armada: systemic cancer therapy using nanomaterials. Nat. Rev. Clin. Oncol. 2010, 7:266.
19. Kostarelos K., Lacerda L., Pastorin G., Wu W., Wieckowski S., Luangsivilay J., Godefroy S., Pantarotto D., Briand J.P., Muller S., Prato M., Bianco A. Cellular uptake of functionalized carbon nanotubes is independent of functional group and cell type. Nat. Nanotechnol. 2007, 2:108.
20. Kam N.W.S., O'Connell M., Wisdom J.A., Dai H.J. Carbon nanotubes as multifunctional biological transporters and near-infrared agents for selective cancer cell destruction. Proc. Natl. Acad. Sci. U. S. A. 2005, 102:11600.
21. Konduru N.V., Tyurina Y.Y., Feng W.H., Basova L.V., Belikova N.A., Bayir H., Clark K., Rubin M., Stolz D., Vallhov H., Scheynius A., Witasp E., Fadeel B., Kichambare P.D., Star A., Kisin E.R., Murray A.R., Shvedova A.A., Kagan V.E. Phosphatidylserine targets single-walled carbon nanotubes to professional phagocytes in vitro and in vivo. PLoS One 2009, 4:e4398.
22. Rosen Y., Elman N.M. Carbon nanotubes in drug delivery: focus on infectious diseases. Expert Opin. Drug Deliv. 2009, 6:517.
23. Prato M., Kostarelos K., Bianco A. Functionalized carbon nanotubes in drug design and discovery. Acc. Chem. Res. 2008, 41:60.
24. Lacerda L., Bianco A., Prato M., Kostarelos K. Carbon nanotubes as nanomedicines: from toxicology to pharmacology. Adv. Drug Deliv. Rev. 2006, 58:1460.
25. Gresser I. A. Chekhov, M.D., and Coley's toxins. N. Engl. J. Med. 1987, 317:457.
26. Wack A., Rappuoli R. Vaccinology at the beginning of the 21st century. Curr. Opin. Immunol. 2005, 17:411.
27. Berzofsky J.A., Terabe M., Wood L.V. Strategies to use immune modulators in therapeutic vaccines against cancer. Semin. Oncol. 2012, 39:348.
28. Medzhitov R., Janeway C.A. Innate immunity: minireview the virtues of a nonclonal system of recognition. Cell 1997, 91:295.
29. Montomoli E., Piccirella S., Khadang B., Mennitto E., Camerini R., De Rosa A. Current adjuvants and new perspectives in vaccine formulation. Expert Rev. Vaccines 2011, 10:1053.
30. Leleux J., Roy K. Micro and nanoparticle-based delivery systems for vaccine immunotherapy: an immunological and materials perspective. Adv. Healthc. Mater. 2013, 2:72.
31. Steinhagen F., Kinjo T., Bode C., Klinman D.M. TLR-based immune adjuvants. Vaccine 2011, 29:3341.
32. Sabbatini P., Tsuji T., Ferran L., Ritter E., Sedrak C., Tuballes K., Jungbluth A.A., Ritter G., Aghajanian C., Bell-McGuinn K., Hensley M.L., Konner J., Tew W., Spriggs D.R., Hoffman E.W., Venhaus R., Pan L., Salazar A.M., Diefenbach C.M., Old L.J., Gnjatic S. Phase I trial of overlapping long peptides from a tumor self-antigen and poly-ICLC shows rapid induction of integrated immune response in ovarian cancer patients. Clin. Cancer Res. 2012, 18:6497.
33. Wong J.P., Christopher M.E., Viswanathan S., Dai X., Salazar A.M., Sun L.Q., Wang M. Antiviral role of toll-like receptor-3 agonists against seasonal and avian influenza viruses. Curr. Pharm. Des. 2009, 15:1269.
34. Garaude J., Blander J.M. "Flagellated" cancer cells propel anti-tumor immunity. Oncoimmunology 2012, 1:71.
35. Chu R.S., Targoni O.S., Krieg A.M., Lehmann P.V., Harding C.V. CpG oligodeoxynucleotides act as adjuvants that switch on T helper 1 (Th1) immunity. J. Exp. Med. 1997, 186:1623.
36. Sun S., Zhang X., Tough D.F., Sprent J. Type I interferon-mediated stimulation of T cells by CpG DNA. J. Exp. Med. 1998, 188:2335.
37. Cooper C.L., Davis H.L., Angel J.B., Morris M.L., Elfer S.M., Seguin I., Krieg A.M., Cameron D.W. CPG 7909 adjuvant improves hepatitis B virus vaccine seroprotection in antiretroviral-treated HIV-infected adults. AIDS 2005, 19:1473.
38. Sogaard O.S., Lohse N., Harboe Z.B., Offersen R., Bukh A.R., Davis H.L., Schonheyder H.C., Ostergaard L. Improving the immunogenicity of pneumococcal conjugate vaccine in HIV-infected adults with a toll-like receptor 9 agonist adjuvant: a randomized, controlled trial. Clin. Infect. Dis. 2010, 51:42.
39. Speiser D.E., Lienard D., Rufer N., Rubio-Godoy V., Rimoldi D., Lejeune F., Krieg A.M., Cerottini J.C., Romero P. Rapid and strong human CD8+ T cell responses to vaccination with peptide, IFA, and CpG oligodeoxynucleotide 7909. J. Clin. Invest. 2005, 115:739.
40. Valmori D., Souleimanian N.E., Tosello V., Bhardwaj N., Adams S., O'Neill D., Pavlick A., Escalon J.B., Cruz C.M., Angiulli A., Angiulli F., Mears G., Vogel S.M., Pan L., Jungbluth A.A., Hoffmann E.W., Venhaus R., Ritter G., Old L.J., Ayyoub M. Vaccination with NY-ESO-1 protein and CpG in Montanide induces integrated antibody/Th1 responses and CD8 T cells through cross-priming. Proc. Natl. Acad. Sci. U. S. A. 2007, 104:8947.
41. Decker W.K., Safdar A. Cytokine adjuvants for vaccine therapy of neoplastic and infectious disease. Cytokine Growth Factor Rev. 2011, 22:177.
42. Parmiani G., Castelli C., Pilla L., Santinami M., Colombo M.P., Rivoltini L. Opposite immune functions of GM-CSF administered as vaccine adjuvant in cancer patients. Ann. Oncol. 2007, 18:226.
43. Clive K.S., Tyler J.A., Clifton G.T., Holmes J.P., Mittendorf E.A., Ponniah S., Peoples G.E. Use of GM-CSF as an adjuvant with cancer vaccines: beneficial or detrimental?. Expert Rev. Vaccines 2010, 9:519.
44. O'Brien L., Perkins S., Williams A., Eastaugh L., Phelps A., Wu J., Phillpotts R. Alpha interferon as an adenovirus-vectored vaccine adjuvant and antiviral in Venezuelan equine encephalitis virus infection. J. Gen. Virol. 2009, 90:874.
45. Reed S.G., Bertholet S., Coler R.N., Friede M. New horizons in adjuvants for vaccine development. Trends Immunol. 2009, 30:23.
46. Del Vecchio M., Bajetta E., Canova S., Lotze M.T., Wesa A., Parmiani G., Anichini A. Interleukin-12: biological properties and clinical application. Clin. Cancer Res. 2007, 13:4677.
47. Rosenberg S.A., Lotze M.T. Cancer immunotherapy using interleukin-2 and interleukin-2-activated lymphocytes. Annu. Rev. Immunol. 1986, 4:681.
48. De Gregorio E., Tritto E., Rappuoli R. Alum adjuvanticity: unraveling a century old mystery. Eur. J. Immunol. 2008, 38:2068.
49. Marrack P., McKee A.S., Munks M.W. Towards an understanding of the adjuvant action of aluminium. Nat. Rev. Immunol. 2009, 9:287.
50. Maslak P.G., Dao T., Krug L.M., Chanel S., Korontsvit T., Zakhaleva V., Zhang R., Wolchok J.D., Yuan J., Pinilla-Ibarz J., Berman E., Weiss M., Jurcic J., Frattini M.G., Scheinberg D.A. Vaccination with synthetic analog peptides derived from WT1 oncoprotein induces T-cell responses in patients with complete remission from acute myeloid leukemia. Blood 2010, 116:171.
51. Jäger E., Jäger D., Knuth A. Antigen-specific immunotherapy and cancer vaccines. Int. J. Cancer 2003, 106:817.
52. Gregoriadis G., Davis D., Davies A. Liposomes as immunological adjuvants: antigen incorporation studies. Vaccine 1987, 5:145.
53. Henriksen-Lacey M., Korsholm K.S., Andersen P., Perrie Y., Christensen D. Liposomal vaccine delivery systems. Expert Opin. Drug Deliv. 2011, 8:505.
54. Plante M., Jones T., Allard F., Torossian K., Gauthier J., St-Felix N., White G.L., Lowell G.H., Burt D.S. Nasal immunization with subunit proteosome influenza vaccines induces serum HAI, mucosal IgA and protection against influenza challenge. Vaccine 2001, 20:218.
55. Teo K.B.K., Singh C., Chhowalla M., Milne W.I. Catalytic synthesis of carbon nanotubes and nanofibers. Encycl. Nanosci. Nanotechnol. 2003, 10:1.
56. Kingston C.T., Simard B. Recent advances in laser synthesis of single-walled carbon nanotubes. J. Nanosci. Nanotechnol. 2006, 6:1225.
57. Fan Y., Goldsmith B.R., Collins P.G. Identifying and counting point defects in carbon nanotubes. Nat. Mater. 2005, 4:906.
58. Ebbesen T.W. Carbon Nanotubes: Preparation and Properties 1997, CRC Press Llc.
59. Hutchison J.L., Kiselev N.A., Krinichnaya E.P., Krestinin A.V., Loutfy R.O., Morawsky A.P., Muradyan V.E., Obraztsova E.D., Sloan J., Terekhov S.V. Double-walled carbon nanotubes fabricated by a hydrogen arc discharge method. Carbon 2001, 39:761.
60. Li Z.H., Wang M., Yang B., Xu Y.B. The influence of different atmosphere gases on the growth and structure of double-walled carbon nanotubes. Inorg. Mater. 2007, 43:475.
61. Deck C.P., Vecchio K. Prediction of carbon nanotube growth success by the analysis of carbon-catalyst binary phase diagrams. Carbon 2006, 44:267.
62. Dupuis A.C. The catalyst in the CCVD of carbon nanotubes - a review. Prog. Mater. Sci. 2005, 50:929.
63. Baker R.T.K., Barber M.A., Harris P.S., Feates S., Waite R.J. Nucleation and growth of carbon deposits from the nickel catalyzed decomposition of acetylene. J. Catal. 1972, 26:51.
64. Bachilo S.M., Balzano L., Herrera J.E., Pompeo F., Resasco D.E., Weisman R.B. Narrow (n, m)-distribution of single-walled carbon nanotubes grown using a solid supported catalyst. J. Am. Chem. Soc. 2003, 125:11186.
65. Chiang I.W., Brinson B.E., Huang A.Y., Willis P., Bronikowski M., Margrave J., Smalley R., Hauge R. Purification and characterization of single-wall carbon nanotubes (SWNTs) obtained from the gas-phase decomposition of CO (HiPco process). J. Phys. Chem. B 2001, 105:8297.
66. Harris P.J.F. Carbon Nanotube Science: Synthesis Properties and Applications 2009, Cambridge University Press, Cambridge.
67. Rinzler A., Liu J., Dai H., Nikolaev P., Huffman C., Rodriguez-Macias F., Boul P., Lu A.H., Heymann D., Colbert D. Large-scale purification of single-wall carbon nanotubes: process, product, and characterization. Appl. Phys. A Mater. Sci. Process. 1998, 67:29.
68. Park T.J., Banerjee S., Hemraj-Benny T., Wong S.S. Purification strategies and purity visualization techniques for single-walled carbon nanotubes. J. Mater. Chem. 2006, 16:141.
69. Ebbesen T.W., Ajayan P.M., Hiura H., Tanigaki K. Purification of carbon nanotubes. Nature 1994, 367:519.
70. Ikazaki F., Ohshima S., Uchida K., Kuriki Y., Hayakawa H., Yumura M., Takahashi K., Tojima K. Chemical purification of carbon nanotubes by the use of graphite intercalation compounds. Carbon 1994, 32:1539.
71. Chen X.H., Chen C.S., Chen Q., Cheng F.Q., Zhang G., Chen Z.Z. Non-destructive purification of multi-walled carbon nanotubes produced by catalyzed CVD. Mater. Lett. 2002, 57:734.
72. Bonard J.-M., Stora T., Salvetat J.-P., Maier F., Stöckli T., Duschl C., Forró L., de Heer W.A., Châtelain A. Purification and size-selection of carbon nanotubes. Adv. Mater. 1997, 9:827.
73. Shelimov K.B., Esenaliev R.O., Rinzler A.G., Huffman C.B., Smalley R.E. Purification of single-wall nanotubes by ultrasonically assisted filtration. Chem. Phys. Lett. 1998, 282:429.
74. Yu A., Bekyarova E., Itkis M.E., Fakhrutdinov D., Webster R., Haddon R.C. Application of centrifugation to the large-scale purification of electric arc-produced single-walled carbon nanotubes. J. Am. Chem. Soc. 2006, 128:9902.
75. Niyogi S., Hu H., Hamon M.A., Bhowmik P., Zhao B., Rozenzhak S.M., Chen J., Itkis M.E., Meier M.S., Haddon R.C. Chromatographic purification of soluble single-walled carbon nanotubes (s-SWNTs). J. Am. Chem. Soc. 2001, 123:733.
76. Duesberg G.S., Burghard M., Muster J., Philipp G. Separation of carbon nanotubes by size exclusion chromatography. Chem. Commun. 1998, 435.
77. Georgakilas V., Voulgaris D., Vazquez E., Prato M., Guldi D.M., Kukovecz A., Kuzmany H. Purification of HiPco carbon nanotubes via organic functionalization. J. Am. Chem. Soc. 2002, 124:14318.
78. Banerjee S., Wong S.S. Rational sidewall functionalization and purification of single-walled carbon nanotubes by solution-phase ozonolysis. J. Phys. Chem. B 2002, 106:12144.
79. Hu H., Zhao B., Itkis M.E., Haddon R.C. Nitric acid purification of single-walled carbon nanotubes. J. Phys. Chem. B 2003, 107:13838.
80. Duesberg G.S., Muster J., Krstic V., Burghard M., Roth S. Chromatographic size separation of single-wall carbon nanotubes. Appl. Phys. A 1998, 67:117.
81. Chen R.J., Zhan Y., Wang D., Dai H. Noncovalent sidewall functionalization of single-walled carbon nanotubes for protein immobilization. J. Am. Chem. Soc. 2001, 123:3838.
82. Andrews R., Jacques D., Qian D., Dickey E.C. Purification and structural annealing of multiwalled carbon nanotubes at graphitization temperatures. Carbon 2001, 39:1681.
83. Green A.A., Hersam M.C. Nearly single-chirality single-walled carbon nanotubes produced via orthogonal iterative density gradient ultracentrifugation. Adv. Mater. 2011, 23:2185.
84. Liu H., Nishide D., Tanaka T., Kataura H. Large-scale single-chirality separation of single-wall carbon nanotubes by simple gel chromatography. Nat. Commun. 2001, 2:309.
85. Lee K.M., Li L., Dai L. Asymmetric end-functionalization of multi-walled carbon nanotubes. J. Am. Chem. Soc. 2005, 127:4122.
86. Zhang Y., Chang A., Cao J., Wang Q., Kim W., Li Y., Morris N., Yenilmez E., Kong J., Dai H. Electric-field-directed growth of aligned single-walled carbon nanotubes. Appl. Phys. Lett. 2001, 79:3155.
87. Badaire S., Poulin P., Maugey M., Zakari C. In situ measurements of nanotube dimensions in suspensions by depolarized dynamic light scattering. Langmuir 2004, 20:10367.
88. Rao A.M., Richter E., Bandow S., Chase B., Eklund P.C., Williams K.A., Fang S., Subbaswamy K.R., Menon M., Thess A., Smalley R.E., Dresselhaus G., Dresselhaus M.S. Diameter-selective Raman scattering from vibrational modes in carbon nanotubes. Science 1997, 275:187.
89. Itkis M.E., Perea D.E., Jung R., Niyogi S., Haddon R.C. Comparison of analytical techniques for purity evaluation of single-walled carbon nanotubes. J. Am. Chem. Soc. 2005, 127:3439.
90. Chiang I.W., Brinson B.E., Huang A.Y., Willis P.A., Bronikowski M.J., Margrave J.L., Smalley R.E., Hauge R.H. Purification and characterization of single-wall carbon nanotubes (SWNTs) obtained from the gas-phase decomposition of CO (HiPco process). J. Phys. Chem. B 2001, 105:8297.
91. Chiang I.W., Brinson B.E., Smalley R.E., Chiang I.W., Brinson B.E., Smalley R.E., Margrave J.L., Hauge R.H. Purification and characterization of single-wall carbon nanotubes. J. Phys. Chem. B 2001, 105:1157.
92. Dillon A.C., Gennett T., Jones K.M., Alleman J.L., Parilla P.A., Heben M.J. A simple and complete purification of single-walled carbon nanotube materials. Adv. Mater. 1999, 11:1354.
93. Singh P., Campidelli S., Giordani S., Bonifazi D., Bianco A., Prato M. Organic functionalisation and characterisation of single-walled carbon nanotubes. Chem. Soc. Rev. 2009, 38:2214.
94. Carbone M., Valentini F., Caminiti R., Petrinca A.R., Donia D., Divizia M., Palleschi G. Are PEI-coated SWCNTs conjugated with hepatitis A virus? A chemical study with SEM, Z-potential, EDXD and RT-PCR. Biomed. Mater. 2010, 5:035001.
95. Meng J., Meng J., Duan J., Kong H., Li L., Wang C., Xie S., Chen S., Gu N., Xu H., Yang X.D. Carbon nanotubes conjugated to tumor lysate protein enhance the efficacy of an antitumor immunotherapy. Small 2008, 4:1364.
96. Georgakilas V., Tagmatarchis N., Pantarotto D., Bianco A., Briand J.P., Prato M. Amino acid functionalisation of water soluble carbon nanotubes. Chem. Commun. 2002, 24:3050.
97. Pantarotto D., Partidos C.D., Graff R., Hoebeke J., Briand J.P., Prato M., Bianco A. Synthesis, structural characterization, and immunological properties of carbon nanotubes functionalized with peptides. J. Am. Chem. Soc. 2003, 125:6160.
98. Pantarotto D., Partidos C.D., Hoebeke J., Brown F., Kramer E., Briand J.P., Muller S., Prato M., Bianco A. Immunization with peptide-functionalized carbon nanotubes enhances virus-specific neutralizing antibody responses. Chem. Biol. 2003, 10:961.
99. Yandar N., Pastorin G., Prato M., Bianco A., Patarroyo M.E., Manuel Lozano J. Immunological profile of a Plasmodium vivax AMA-1 N-terminus peptide-carbon nanotube conjugate in an infected Plasmodium berghei mouse model. Vaccine 2008, 26:5864.
100. Villa C.H., Dao T., Ahearn I., Fehrenbacher N., Casey E., Rey D.A., Korontsvit T., Zakhaleva V., Batt C.A., Philips M.R., Scheinberg D.A. Single-walled carbon nanotubes deliver peptide antigen into dendritic cells and enhance IgG responses to tumor-associated antigens. ACS Nano 2011, 5:5300.
101. Zeinali M., Jammalan M., Ardestani S.K., Mosaveri N. Immunological and cytotoxicological characterization of tuberculin purified protein derivative (PPD) conjugated to single-walled carbon nanotubes. Immunol. Lett. 2009, 126:48.
102. Mocan T., Iancu C. Effective colon cancer prophylaxis in mice using embryonic stem cells and carbon nanotubes. Int. J. Nanomedicine 2011, 6:1945.
103. May R.J., Dao T., Pinilla-Ibarz J., Korontsvit T., Zakhaleva V., Zhang R.H., Maslak P., Scheinberg D.A. Peptide epitopes from the Wilms' tumor 1 oncoprotein stimulate CD4+ and CD8+ T cells that recognize and kill human malignant mesothelioma tumor cells. Clin. Cancer Res. 2007, 13:4547.
104. Krug L.M., Dao T., Brown A.B., Maslak P., Travis W., Bekele S., Korontsvit T., Zakhaleva V., Wolchok J., Yuan J.D., Li H., Tyson L., Scheinberg D.A. WT1 peptide vaccinations induce CD4 and CD8 T cell immune responses in patients with mesothelioma and non-small cell lung cancer. Cancer Immunol. Immunother. 2010, 59:1467.
105. Ruggiero A., Villa C.H., Bander E., Rey D.A., Bergkvist M., Batt C.A., Manova-Todorova K., Deen W.M., Scheinberg D.A., McDevitt M.R. Paradoxical glomerular filtration of carbon nanotubes. Proc. Natl. Acad. Sci. U. S. A. 2010, 107:12369.